# First in Man Trial of BI 113608

> **NCT01540825** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 80 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 113608
- **DRUG:** BI 113608
- **DRUG:** BI 113608
- **DRUG:** BI 113608
- **DRUG:** Placebo
- **DRUG:** BI 113608
- **DRUG:** BI 113608
- **DRUG:** BI 113608
- **DRUG:** BI 113608
- **DRUG:** BI 113608
- **DRUG:** BI 113608

## Key facts

- **NCT ID:** NCT01540825
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-02
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2017-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01540825

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01540825, "First in Man Trial of BI 113608". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01540825. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*